Background: The Polycomb group (PcG) of proteins is a family of important developmental regulators. The respective members function as large protein complexes involved in establishment and maintenance of transcriptional repression of developmental control genes. MBTD1, Malignant Brain Tumor domain-containing protein 1, is one such PcG protein. MBTD1 contains four MBT repeats.
Introduction
The nucleosome is the fundamental repeating unit of chromatin. The nucleosome core particle consists of approximately 147 base pairs of DNA wrapped around a histone octamer consisting of 2 copies each of the core histones H2A, H2B, H3, and H4. The four core histones are composed of a globular domain and an unstructured tail. The unstructured tails protrude from the nucleosome and are subject to a number of post-translational modifications including acetylation, methylation, phosphorylation and ubiquitylation [2] . Methylation of lysine and arginine residues on the histones is an important regulator of eukaryotic transcription and genome integrity. These post-translational modifications are thought to act as markers that recruit proteins to specific regions of chromatin [3] .
The MBT (Malignant Brain Tumor) repeat is a structural motif of ,100 amino acids that is conserved from C. elegans to humans and exists as tandem repeats [4] . In the human genome, there are at least 9 MBT repeat proteins, each containing two, three or four MBT repeats, respectively. The MBT repeat was originally identified in the Drosophila tumor-suppressor protein L(3)MBT and mutations of L(3)MBT gene cause malignant transformations of the optic neuroblasts [5] . Like other members in the 'Royal Family' [6] , MBT repeat proteins have been shown to recognize methylated lysine residues on histones [7] , and functional studies have suggested important connections between MBT domaincontaining proteins and the transcriptional state of chromatin regions [8, 9, 10, 11, 12, 13] .
Structural studies of MBT repeat proteins show that, unlike chromodomain [14, 15, 16, 17] , MBT repeat proteins use a semiaromatic cage to accommodate the methyllysine [1, 9, 18, 19, 20, 21] . The difference in the residue composition of the binding pocket of the histone code effectors allows them to discriminate between different lysine methylation states [19] . The chromodomain proteins preferentially bind trimethylated lysine histones whereas MBT repeats show specificity towards the lower methylation states of lysine. To gain insight into the conservation of the semiaromatic cage and its function in methyl recognition, we have determined the structure of the 4-MBT repeat domain of human MBTD1 and characterized its binding specificity against different histone peptides.
Results and Discussion
MBTD1 is a four MBT repeat protein comprising 628 amino acids. It contains a FCS-type zinc finger at the N-terminus with putative regulatory function [22] and four MBT repeats at the C-terminus. To investigate the crystal structure of the four MBT repeat fragment of MBTD1 and characterize its histone binding specificity, we cloned and purified a human MBTD1 fragment composed of all four MBT repeats (residues 130-566). MBTD1 130-566 crystallized in the orthorhombic space group P2 1 2 1 2 1 (a = 70.31 Å , b = 100.90 Å , c = 135.30 Å ) with two molecules in the asymmetric unit ( Figure 1 ). Crystal diffraction data and refinement statistics for the MBTD1 structure are displayed in Table 1 . In the MBTD1 structure, each molecule contains four MBT repeats that exhibit irregular rhomboid architecture. A narrow channel runs through the middle of the structure and is filled with water molecules. Consistent with previously reported MBT repeat structures, each MBT repeat contains an extended ''arm'' which packs against a globular b subunit core of the preceding repeat [1] . Structural and sequence alignment show that the b-barrel subunit core region has the highest conservation between MBTD1 and other MBT repeat proteins. The residues involved in intermolecular hydrogen bond interactions between the two molecules in the asymmetric unit are conserved throughout the whole MBT repeat family, possibly implying that MBTD1 functions as a dimer unit (Figure 2 ). Nonetheless, dynamic light scattering (DLS) experiments and size exclusion experiments demonstrate that MBTD1 is a monomer in solution at the working concentrations (,5 mg/ml, data not shown). Structurally, the last three MBT repeats in MBTD1 and L3MBTL2 form threeblade propeller architecture. Superposition of the three MBT repeats of L3MBTL1 with those of MBTD1 and L3MBTL2 shows a good structural alignment of Ca positions with a rootmean-squared deviation (RMSD) of 2.345 Å and 2.168 Å , respectively. Furthermore, the MBTD1 can also be well superimposed with L3MBTL2 with a root-mean-squared deviation of 0.697 Å .
To date, L3MBTL1 [18, 20, 23] , L3MBTL2 [1] , dScm [9] , dSFMBT [13] and SCML2 [21] have been shown to selectively bind lower methylated histone tails. To explore if MBTD1 also possesses histone binding ability, we have carried out the binding studies of the MBTD1 4MBT fragment against a set of fluorescently labeled peptides derived from the N-terminal tails of histones H3 and H4 by means of fluorescence polarization technique ( Figure 3 ). The data revealed that MBTD1 specifically binds to mono and di-methylated lysine on histone H4K20 and exhibit negligible binding to the unmodified or trimethylated peptides. Furthermore, the binding results also show that MBTD1 weakly interacts with mono-or dimethylated lysine histone peptides H3K9, H3K4 and H3K27. This indicates that MBTD1 modestly selectively recognizes lower methylated H4K20 peptide over other histone lysine methylation sites.
Although the four MBT repeats of MBTD1 have similar three-dimensional structures and high sequence identity, only the fourth MBT repeat (MBT4) contains the semi-aromatic cage, which is formed by the loops between the first and second strands and the third and fourth strands of the b-barrel core domain and constitutes the binding site for methyllysine residue, analogous to L3MBTL2. The binding pocket of the MBTD1-MBT4 is shown in Figure 4 , where an open cage in MBTD1 is formed by aromatic residues Phe526, Trp529, Tyr533, negatively charged Asp502, and Leu508. Three highly conserved aromatic residues Phe526, Trp529 and Tyr533 form the base and the walls of the hydrophobic pocket. Interestingly, Arg325 from a symmetry related molecule is inserted into the binding pocket, mimicking the methyl-lysine binding in L3MBTL2 [1] . The arginine residue 325 is stabilized by a salt bridge with the pocket residue Asp502, and cation-p and van der Waals and interactions with the aromatic cage residues.
The utilization of a single MBT repeat for histone binding, despite the structural and sequence similarity shared by all four MBT repeats, is reminiscent of the histone binding mode employed by other MBT containing proteins, including L3MBTL1 [18, 20] . This has been explored in parallel to MBTD1, where only the second MBT domain (MBT2) of the three MBT repeats in L3MBTL1 was bound to histone peptide. Based on sequence and structural alignment, we attributed this phenomenon to the steric hindrance generated by the long or bulky side chain residues (phenylalanine in MBT1 and arginine in MBT3) in the potential pockets instead of cysteine in MBT2. We also suggested that the electrostatic repulsion between the methyllysine and Arginine in MBT3 might be an additional factor, which prevents histone peptide binding. To test our hypothesis and to explore the possibilities of converting a naturally ''non-functional'' methyllysine binding MBT to a ''functional'' state, we generated a L3MBTL1 Arg467Cys mutant, which in principle should eliminate both the steric hindrance and electrostatic repulsion in MBT3 based on our prediction. Crystals of the L3MBTL1 R467C mutant were successfully grew in the presence of excess amount of H4K20me2 peptide. However, no electron density was observed in the predicted binding site in the mutated MBT3. ITC experiment of this mutant titrated with H4K20me2 also suggests that there is only one binding site (data not shown). Upon a closer examination of this mutant crystal structure, another residue Arg461 was identified, which potentially clashes with Arg17 on the histone peptide and therefore prevent the methylated lysine histone from binding in this pocket ( Figure 5 ). In MBT2, the same position is occupied by Met357. All known MBT-peptide complex structures characterized to date do not exhibit strong histone peptide sequence selectivity, and use a ''cavity insertion recognition mode'' to recognize the methylated lysine with the deeply buried methyl-lysine forming extensive interactions with the protein while the peptide residues flanking methyl-lysine forming very few contacts [1] . Although a ''functional'' MBT3 was not obtained, this mutagenesis study revealed that the histone peptide could not bind to MBT repeats in any orientation.
Materials and Methods

Protein expression and purification
The human MBTD1 protein (residues 130-566) was subcloned into pET28a-MHL vector and transformed in Escherichia coli BL21 (DE3)-V2R-pRARE2. Cells were grown in Luria-Bertanin media at 37uC until they reach an absorbance at 600nm of approximately 3.0, then cooled down to 14uC followed by induction with 1 mM of isopropyl-b-D-thiogalactoside (IPTG) overnight. Cells were harvested by centrifugation at 7500 rpm for 15 minutes, resuspended in a buffer solution containing 20 mM Tris 8.0, 250 mM NaCl, 10% glycerol and lyzed by sonication. The supernatant fraction obtained by centrifugation at 16,000 rpm for 1 hour and passed through a Ni-NTA Superflow resin (QIAGEN) that had been pre-equilibrated in 20 mM Tris-HCl (pH 8.0), 250 mM NaCl, 10% Glycerol, which was then washed and eluted with 20 mM Tris-HCl (pH 8.0), 250 mM NaCl, 10% Glycerol, 500 mM imidazole. HiTrap Q HP column (GE Healthcare, Piscataway, NJ) and Superdex 75 gel-filtration column (GE Healthcare, Piscataway, NJ) were carried out for further purification. The protein was concentrated to 10 mg/ml in a buffer containing 20 mM Tris-HCl, pH 8.0, 0.2 M NaCl, 10% Glycerol, 1 mM EDTA and 1 mM DTT. The human L3 MBTL1 R467C mutants containing 3 MBT repeats (residues 200-522, 3MBT) were generated by Stratagene's QuikChange method. The mutant protein was expressed and purified as previously described [20] . Fluorescence polarization assays were performed as described in [24] .
Protein crystallization and Structure determination
Crystals of MBTD1 were obtained by macroseeding at 18uC by vapor diffusion of hanging drops of 5 ml of 10 mg ml 21 protein solution mixed with 5 ml of a reservoir solution. The reservoir solution contained 20% PEG 3350, 0.2M CaOAc. For cryoprotection, crystals were soaked for a few seconds in a reservoir solution containing 20% (wt/vol) glycerol. The crystals were mounted in a cryoloop and subsequently flash-frozen in liquid nitrogen. X-ray data were collected at 100 K on beamline 23ID-B of Advance Photon Source (APS) at Argonne National Laboratory. A native data set was collected to 2.5 Å resolution. The crystal belongs to space group P212121, with unit cell parameters a = 70.31 Å , b = 100.90 Å , and c = 135.30 Å . There are two molecules in the asymmetric unit that have a VM of 2.42 Å 3 Da2 1 and a solvent content of 48.2%. The structure of MBTD1 was determined by molecular replacement using PHASER [25] using the crystal structure of L3MBTL2 (PDB code 3f70) as a search model. Automated building was done with ARP/wARP [26] and manual intervention for corrections. Refinement was carried out using REFMAC [27] in CCP4.
The progress of refinement was monitored with Rfree and inspection of 2|Fo|2|Fc| and |Fo|2|Fc| maps in COOT [28] . When Rfree reached 29.8%, TLS refinement was applied and the Rfree dropped to 27.4%. Stereochemical analysis was done with Molprobity. The human L3MBTL1 R467C mutant crystals were grown and its structure was solved using the same methods as we previously reported for their wild-type counterpart [20] .
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